Astellas Pharma Statistics Share Statistics Astellas Pharma has 1.8B
shares outstanding. The number of shares has increased by 0.03%
in one year.
Shares Outstanding 1.8B Shares Change (YoY) 0.03% Shares Change (QoQ) 0.01% Owned by Institutions (%) n/a Shares Floating 1.75B Failed to Deliver (FTD) Shares 111,433 FTD / Avg. Volume 66.69%
Short Selling Information The latest short interest is 350.36K, so 0% of the outstanding
shares have been sold short.
Short Interest 350.36K Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is 51.29 and the forward
PE ratio is 0.13.
Astellas Pharma's PEG ratio is
0.26.
PE Ratio 51.29 Forward PE 0.13 PS Ratio 1.36 Forward PS 0 PB Ratio 1.72 P/FCF Ratio 18.97 PEG Ratio 0.26
Financial Ratio History Enterprise Valuation Astellas Pharma has an Enterprise Value (EV) of 3,246B.
EV / Sales 1.7 EV / EBITDA 13.09 EV / EBIT 16.69 EV / FCF 23.66
Financial Position The company has a current ratio of 1.13,
with a Debt / Equity ratio of 0.55.
Current Ratio 1.13 Quick Ratio 0.85 Debt / Equity 0.55 Debt / EBITDA 3.35 Debt / FCF 6.06 Interest Coverage 2.32
Financial Efficiency Return on Equity is 3.35% and Return on Invested Capital is 2.62%.
Return on Equity 3.35% Return on Assets 1.52% Return on Invested Capital 2.62% Revenue Per Employee $129.61M Profits Per Employee $3.44M Employee Count 14,754 Asset Turnover 0.57 Inventory Turnover 1.17
Taxes Income Tax -19.51B Effective Tax Rate -62.46%
Stock Price Statistics The stock price has increased by -0.81% in the
last 52 weeks. The beta is 0.12, so Astellas Pharma's
price volatility has been higher than the market average.
Beta 0.12 52-Week Price Change -0.81% 50-Day Moving Average 9.83 200-Day Moving Average 9.92 Relative Strength Index (RSI) 77.44 Average Volume (20 Days) 167,103
Income Statement In the last 12 months, Astellas Pharma had revenue of 1,912.3B
and earned 50.75B
in profits. Earnings per share was 28.35.
Revenue 1,912.3B Gross Profit 1,563.1B Operating Income 41.04B Net Income 50.75B EBITDA 248.05B EBIT 48.91B Earnings Per Share (EPS) 28.35
Full Income Statement Balance Sheet The company has 188.37B in cash and 831.43B in
debt, giving a net cash position of -643.05B.
Cash & Cash Equivalents 188.37B Total Debt 831.43B Net Cash -643.05B Retained Earnings 740.94B Total Assets 3,339.5B Working Capital 139.74B
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was 194.51B
and capital expenditures -57.33B, giving a free cash flow of 137.18B.
Operating Cash Flow 194.51B Capital Expenditures -57.33B Free Cash Flow 137.18B FCF Per Share 76.34
Full Cash Flow Statement Margins Gross margin is 81.74%, with operating and profit margins of 2.15% and 2.65%.
Gross Margin 81.74% Operating Margin 2.15% Pretax Margin 1.63% Profit Margin 2.65% EBITDA Margin 12.97% EBIT Margin 2.15% FCF Margin 7.17%
Dividends & Yields ALPMY pays an annual dividend of $0.32,
which amounts to a dividend yield of 2.77%.
Dividend Per Share $0.32 Dividend Yield 2.77% Dividend Growth (YoY) -1.09% Payout Ratio 167.61% Earnings Yield 1.95% FCF Yield 5.27%
Dividend Details Analyst Forecast Currently there are no analyst rating for ALPMY.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value $141.75 Lynch Upside 1185.13% Graham Number 731.49 Graham Upside 6531.82%
Stock Splits The last stock split was on Apr 2, 2014. It was a
forward
split with a ratio of 5:4.
Last Split Date Apr 2, 2014 Split Type forward Split Ratio 5:4
Scores Altman Z-Score 1.16 Piotroski F-Score 7
